Tesamorelin COA: Check Identity, Declared Form and Lot

Biohacking Elite logo

Published by Biohacking Elite · November 17, 2026. No specialist review is claimed.

In brief: A tesamorelin COA should name the exact material and declared form, connect the tested sample to the supplier lot, and report identity and purity results with their methods. The correct spelling is tesamorelin; the common misspelling “tesamorline” is worth checking for on labels and reports, because a name mismatch is itself a documentation gap. This Biohacking Elite guide covers document review for research materials only.

Key points

  • Confirm the spelling, declared form (for example, free base or a stated salt) and any modification on every document.
  • Match the report’s sample ID to the supplier lot printed on the unit.
  • Read mass-spectrometry identity results against the declared form, not just the compound name.
  • Keep HPLC purity, peptide content and labeled fill amount as separate questions.

This article addresses analytical documentation, not biological effects. Compare the tesamorelin research-library listing with the supplier’s current specification and the lot-linked report before accepting material into a laboratory inventory.

Start With the Name and the Declared Form

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) that carries a defined N-terminal modification. ChEBI:63626 describes that modification as a hex-3-enoyl group attached to the N-terminal tyrosine of the 44-residue human GRF sequence. For document review, the practical point is that “tesamorelin” refers to a specific modified sequence, so the COA should describe that material unambiguously rather than relying on a catalog nickname.

Check that the label, specification and report use the same spelling and the same material description. Online listings sometimes use “tesamorline”; a report that uses a different name or spelling from the label should be clarified in writing, not assumed to describe the same material.

Also note the declared form. Peptides may be supplied as a free base or as a salt such as an acetate, and the form changes the expected molecular weight and how content results are expressed. If the report does not state the form, record that as an open question.

Research Material Is Not the Approved Drug Product

A prescription drug product containing tesamorelin has been approved in the United States; official labeling for one such finished product is published on DailyMed. That prescribing information describes a specific regulated product; it is not a certificate of analysis for any research lot, and a research material is not that product. Keep the two document types apart in your records, and do not cite approved-product labeling as evidence about a research lot’s identity or purity.

Match the Report to the Supplier Lot

Collect the supplier lot number, the laboratory sample ID, the report number and version, and the test dates. These identifiers do not need identical formats, but the mapping between them should be documented. The COA field guide explains each of the standard fields.

Check whether the tested sample was bulk material or a finished, filled unit. A bulk report can characterize the upstream material without establishing what is in an individual container. Where the issuing laboratory offers report lookup, confirm the document on the laboratory’s own site using the steps in the peptide COA verification guide and the confirmed pages in where to verify a COA, by lab.

Read Identity Evidence Against the Exact Material

An HPLC purity percentage does not by itself confirm identity. The EMA synthetic-peptides guideline treats characterisation and identity as a separate analytical question from chromatographic purity. Identity evidence for a modified peptide usually comes from mass spectrometry, where the observed mass is compared with the theoretical mass for the declared sequence, modification and form. The LC-MS peptide testing guide explains what that comparison can and cannot show.

Look for the observed value, the expected value, the ion or charge state reported, and the acceptance criterion. A single number with no reference value, or an expected value that does not match the declared form, should be raised with the supplier before the material is accepted.

Separate Purity, Content and Fill Amount

Chromatographic purity describes the proportion of the main peak relative to detected peaks under one method. It is not the same as peptide content (how much of the material’s mass is the peptide rather than counter-ions, water or other components), and neither one is the same as the labeled fill amount per unit. The purity-percentage guide covers how the HPLC figure is produced.

A report that states only “purity” without the method, detection wavelength or chromatogram gives limited information. If content or fill amount is claimed, the report should say how it was measured and which sample was tested.

A Short Discrepancy Checklist

Tesamorelin COA review — common gaps
CheckWhat a gap looks like
Name and spellingLabel, specification and report use different names or spellings
Declared formNo statement of free base, salt or modification
Lot linkageNo supplier lot on the report, or no documented sample-to-lot mapping
Identity evidencePurity result only, with no mass-spectrometry data or expected value
Method detail“Passes” or “tested” with no method, result, unit or acceptance criterion
IssuerNo identifiable laboratory, report number or way to confirm the report

Document the Conclusion Without Extrapolating

Record what the report supports: the material description, lot, methods, results and any open questions. A complete COA supports a documentation decision about one lot; it does not describe how that lot was stored after release, and it says nothing about biological activity. Unresolved gaps should stay visible in the acceptance record until the supplier answers them.

Frequently asked questions

Is “tesamorline” a different compound?

No. It is a common misspelling of tesamorelin. On formal documents, a spelling or naming difference should still be clarified so the label, specification and report clearly describe the same material.

Does a high HPLC purity confirm the material is tesamorelin?

No. HPLC purity measures the main peak relative to other detected peaks. Identity needs separate evidence, typically mass spectrometry compared against the expected mass for the declared form.

Can approved-drug labeling stand in for a research COA?

No. Prescribing information describes a specific approved finished product. It is not analytical evidence about any research lot.

What if the report does not name the supplier lot?

Hold the material and request, in writing, the report that matches the labeled lot or documentation that maps the tested sample to that lot. Record the request and the answer.

Sources

These sources are documentation references. They describe official quality, analytical or chemical-identification frameworks and are not product approvals; they do not apply automatically to research-use-only materials.

Research use only: Research materials discussed here are for qualified laboratory research only, not for human or veterinary use. This article concerns documentation and analytical review, not personal-use instructions.

Leave a Comment

Your email address will not be published. Required fields are marked *

For laboratory research use only. Not for human or veterinary use.
Scroll to Top